Ascension Ventures helped add $6m to a round for the telemedicine technology provider already featuring Cigna and MemorialCare Health.

Section 32 has led a $46.7m series B round that will support further development of the MIT spinout's biosensor-based diagnostics device.

Intermountain Ventures, already among the medical chatbot developer's customers, participated in a $13.6m round that took its total funding past $20m.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The ophthalmologic drug developer has gone public three years after being founded by WuXi AppTec-backed 6 Dimensions Capital.

Pfizer Ventures, billed as an existing investor, contributed to the $72.5m close of the antibody-drug conjugate developer's latest round.

The ultrasound system developer's Edwards Lifesciences-backed series B round will fund product development and commercial growth.

Gilead Sciences returned for a $46.7m round that will support further development of its biosensor-based diagnostics device.

University of Toronto and McMaster University-founded glioblastoma Car T-cell therapy developer Empirca Therapeutics has been acquired by Century Therapeutics.

University of Birmingham's cancer immunotherapy developer Revitope Oncology secured equity funding as part of a $160m alliance with Junshi Biosciences.